Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ATP4A | P20648 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | ATP4B | P51164 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.65 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL534522 | 1.00 | SLC47A1 (0.65) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL534521 | 1.00 | SLC47A1 (0.65) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10855579 | 1.00 | SLC47A1 (0.65) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL11156751 | 0.99 | SLC47A1 (0.64) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL11156749 | 0.99 | SLC47A1 (0.64) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| SCHEMBL10338624 | 0.94 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| SCHEMBL11527651 | 0.93 | HRH2 (0.63) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| SCHEMBL11527648 | 0.93 | HRH2 (0.63) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL11074155 | 0.90 | HRH2 (0.68) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| SCHEMBL11073364 | 0.90 | SLC47A1 (0.55) | SLC47A1HRH2MEN1SLC22A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114975-B1 | FASCIN-2 (FSCN2) VARIANT AND USE THEREOF | REGENERON PHARMA (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3793518-B1 | AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES | FERTIN PHARMA AS (DK) | 2025-03-26 | — | — | EP | claimed |
| EP-3784214-B1 | LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-11-13 | — | — | EP | claimed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | claimed |
| EP-3866770-B1 | NOVEL DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-10-09 | — | — | EP | claimed |
| EP-3791862-B1 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | EAGLE BIOLOGICS INC (US) | 2024-05-29 | — | — | EP | claimed |
| EP-3970703-B1 | NOVEL NANOPARTICLES USING ANIONIC POLYMER, PREPARATION METHOD AND COMPOSITION THEREOF | IMGT CO LTD (KR) | 2024-02-07 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| EP-3836905-B1 | NOVEL ORAL COMPOSITION | APILLET APS (DK) | 2023-10-04 | — | — | EP | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| EP-3793534-B1 | AN ORAL TABLET FOR DELIVERY OF ACTIVE INGREDIENTS TO THE GASTROINTESTINAL TRACT | FERTIN PHARMA AS (DK) | 2023-04-05 | — | — | EP | claimed |
| EP-3972591-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-4061304-A1 | MULTI-CHAMBER CONTAINER | Rupprecht, Holger (DE) | 2022-09-28 | — | — | EP | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3534880-B1 | LIQUID ORAL PHARMACEUTICAL DOSAGE FORM COMPRISING AN HISTAMINE H2-RECEPTOR ANTAGONIST AND AN ANTACID | JOHNSON & JOHNSON CONSUMER INC (US) | 2022-05-18 | — | — | EP | claimed |